These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
370 related articles for article (PubMed ID: 16097091)
21. Regulators need to regulate. For health and safety issues, the nation needs watchdogs to be on guard. May D Mod Healthc; 2010 Mar; 40(9):16. PubMed ID: 20344831 [No Abstract] [Full Text] [Related]
22. EU directive on clinical trials penalizes small sponsors. Meldolesi A Nat Biotechnol; 2003 Aug; 21(8):838. PubMed ID: 12894186 [No Abstract] [Full Text] [Related]
23. Remarks at the Food and Drug Law Institute's 48th Annual Conference. Niedelman SM Food Drug Law J; 2005; 60(2):117-26. PubMed ID: 16097089 [No Abstract] [Full Text] [Related]
24. US voters' love of Canada's Internet drugstores making politicians cautious. Whitwham B CMAJ; 2003 Apr; 168(8):1033. PubMed ID: 12695403 [No Abstract] [Full Text] [Related]
26. Introduction: public and private sector collaboration in the field of contraceptive research and development. Segal S Rev Law Soc Change; 1997; 23(3):329-37. PubMed ID: 10725051 [No Abstract] [Full Text] [Related]
27. E-health & pharmaceuticals. Appleby C Health Forum J; 2001; 44(1):17-21. PubMed ID: 11225552 [TBL] [Abstract][Full Text] [Related]
28. The GATT TRIPS Agreement and health care in India. Otten A Natl Med J India; 1995; 8(1):1-3. PubMed ID: 7696937 [No Abstract] [Full Text] [Related]
29. Pediatric drug development in anesthesiology: an FDA perspective. Schultheis LW; Mathis LL; Roca RA; Simone AF; Hertz SH; Rappaport BA Anesth Analg; 2006 Jul; 103(1):49-51. PubMed ID: 16790624 [No Abstract] [Full Text] [Related]
30. Pharmacometrics at FDA: evolution and impact on decisions. Powell JR; Gobburu JV Clin Pharmacol Ther; 2007 Jul; 82(1):97-102. PubMed ID: 17538553 [TBL] [Abstract][Full Text] [Related]
31. Sandoz sues FDA over delay in first biogeneric approval. Fox JL Nat Biotechnol; 2005 Nov; 23(11):1327-8. PubMed ID: 16273046 [No Abstract] [Full Text] [Related]
32. A study in futility: Abigail Alliance for Better Access to Developmental Drugs will not expand access to experimental drugs for the terminally ill. Ochs A Seton Hall Law Rev; 2009; 39(2):559-603. PubMed ID: 19462540 [No Abstract] [Full Text] [Related]
33. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk. Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527 [No Abstract] [Full Text] [Related]
34. Regulation of online pharmacy: an Australian perspective. Bernath P J Law Med; 2003 Feb; 10(3):339-63. PubMed ID: 12650004 [TBL] [Abstract][Full Text] [Related]
35. Recombinant protein therapeutics--success rates, market trends and values to 2010. Pavlou AK; Reichert JM Nat Biotechnol; 2004 Dec; 22(12):1513-9. PubMed ID: 15583654 [No Abstract] [Full Text] [Related]
36. The safe harbor provision of the Hatch-Waxman Act: present scope, new possibilities, and international considerations. Coggio BD; Cerrito FD Food Drug Law J; 2002; 57(2):161-76. PubMed ID: 12436981 [No Abstract] [Full Text] [Related]
37. Vision and will: the future of the FDA. Epstein D Oncologist; 2009 Apr; 14(4):317-9. PubMed ID: 19365098 [No Abstract] [Full Text] [Related]
38. The unfinished business of U.S. drug safety regulation. Evans BJ; Flockhart DA Food Drug Law J; 2006; 61(1):45-63. PubMed ID: 16838457 [No Abstract] [Full Text] [Related]
39. The special treatment. Osborne R Nat Biotechnol; 2008 May; 26(5):487-9. PubMed ID: 18464770 [No Abstract] [Full Text] [Related]
40. Remarks delivered at the Food and Drug Law Institute's 48th Annual Conference. Enzi MB Food Drug Law J; 2005; 60(2):103-6. PubMed ID: 16097090 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]